Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Embolic protection for AMI (acute myocardial infarction) population:

This article was originally published in Clinica

Executive Summary

Medtronic has begun a clinical trial to test a smaller version of its embolic protection device that may be especially useful during percutaneous interventional procedures in patients who have experienced an acute myocardial infarction (AMI). The 500-patient, multicentre, prospective, randomised study, called EMERALD, will assess the firm's 0.028 inch GuardWire Plus temporary occlusion and aspiration system. The company's 0.036 GuardWire has been available in the US since last year. The new trial is the first to evaluate a distal protection system during percutaneous intervention in patients who have experienced AMI, says Medtronic. Worldwide, patients with AMIs represent 25% of all coronary vascular interventions, the company adds.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT066575

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel